The Pipeline for New TB Regimens: Better than Ever Is Not Good Enough

The Pipeline for New TB Regimens: Better than Ever Is Not Good Enough

Interactive Data Dashboards

Track the HIV & TB response

Live indicators, province breakdowns and downloadable data.

  • The Pipeline for New TB Regimens: Better than Ever Is Not Good Enough

    In December 2012, tuberculosis (TB) treatment reached a major milestone with the first approval in over forty years of a new medication from a novel class of TB drugs. The US Food and Drug Administration (FDA) approval of bedaquiline reflects a newly revitalised global effort to develop fresh, more effective treatments for TB after decades…

    ·

  • Rifapentine: Trialled in SA but not available in SA

    A new tuberculosis treatment regimen has been shown to be safe and effective in a clinical trial conducted in southern Africa. However, the high cost and a lack of clear support from producers mean that access to the drug in the South African public sector is unlikely for years to come. The RIFAQUIN trial Tuberculosis…

    ·

  • TB in South African prisons: WHERE TO NOW?

    South Africa stands at a crossroads in the fight against tuberculosis. An important victory in the Constitutional Court has affirmed the direction that we should take, but we need sustained political will and activism to ensure that we do not squander this momentum.  The Dudley Lee case Dudley Lee spent over four years in Pollsmoor…

    ·

  • HOW YOU CAN USE AIDS COUNCILS TO STOP TB

    By getting involved, you can ensure that AIDS Councils improve the quality of tuberculosis services in your district Step 1: Get involved One of the key ideas in the NSP is the provision of structures that channel communication up from districts to provinces, and from provinces to the national level. Most people can get involved…

    ·

  • GeneXpert: An imperfect rollout

    The GeneXpert tuberculosis (TB) test promises to revolutionise TB detection in South Africa. But will the rollout and implementation of this new system be good enough to fulfil its potential? “If a minister can do it, it can’t be that hard,” said Health Minister Aaron Motsoaledi in March 2011 as he launched the rollout of…

    ·

  • Decentralising DR-TB care: how far along are we?

    In August 2011, the Department of Health announced a new policy for the decentralised management of drug-resistant tuberculosis. If this plan is put into action as intended, it could be a major step forward in South Africa’s fight against the disease. But almost two years on, implementation remains patchy. What is the policy of decentralising…

    ·

  • TB in the NSP: Are we meeting the targets?

    “Reduce the number of new TB infections as well as deaths from TB by 50%” – a key target of the NSP 2012–2016 The first year of the five-year National Strategic Plan for HIV, TB and STIs (NSP), launched in December 2011, has come to an end. Now is an important time to reflect on…

    ·

  • TB and the NSP

    What will it take to control TB in South African prisons? In 1903 the New York Times claimed that sending people to jail condemned prisoners both to hard labour and tuberculosis (TB) infection. Approximately 40-60% of all jail deaths at the time were due to TB, and most autopsy findings showed evidence of infection with…

    ·

  • TAC’s work in schools

    Not enough is being done to educate teenagers on HIV, sexuality and teenage pregnancy in our schools. This is unacceptable since teens are at high risk of contracting HIV both through consensual sex and sexual abuse. As a result, the Treatment Action Campaign (TAC) in Ekurhuleni has been hard at work informing young people about…

    ·

  • Better ways to pay for research

    A treaty aimed at improving the way that medical research is funded gathered significant momentum, before it was derailed at a World Health Organization meeting last November. Despite this setback, there are some reasons to hope for progress. What is wrong with the current system? The current system of medical innovation relies mainly on incentives…

    ·

  • Upping the competition

    For a second successive tender, the Department of Health has managed to negotiate much lower prices for the antiretrovirals used in the public health system. It’s hard to envy Anban Pillay’s position. As deputy director-general for health regulation and compliance in the National Department of Health (DoH), Pillay is responsible for overseeing key pharmaceutical tenders,…

    ·